AIMS/HYPOTHESIS: Estimated glomerular filtration rate (eGFR) predicts mortality in non-diabetic populations, but its role in people with type 2 diabetes is unknown. We assessed to what extent a reduction in eGFR in people with type 2 diabetes predicts 11-year all-cause and cardiovascular mortality, independently of AER and other cardiovascular risk factors. MATERIALS AND METHODS: The study population was the population-based cohort (n = 1,538; median age 68.9 years) of the Casale Monferrato Study. GFR was estimated by the abbreviated Modification of Diet in Renal Disease Study equation. RESULTS: At baseline, the prevalence of chronic kidney disease (eGFR <60 ml min(-1) 1.73 m(-2)) was 34.3% (95% CI 33.0-36.8). There were 670 deaths in 10,708 person-years of observation. Hazard ratios of 1.23 (95% CI 1.03-1.47) for all-cause mortality and 1.18 (95% CI 0.92-1.52) for cardiovascular mortality were observed after adjusting for cardiovascular risk factors and AER. When five levels of eGFR were analysed we found that most risk was conferred by eGFR 15-29 ml min(-1) 1.73 m(-2), whereas no increased risk was evident in people with eGFR values between 30 and 59 ml min(-1) 1.73 m(-2). In an analysis stratified by AER categories, a significant increasing trend in risk with decreasing eGFR was evident only in people with macroalbuminuria. CONCLUSIONS/ INTERPRETATION: Our study suggests that in type 2 diabetes macroalbuminuria is the main predictor of mortality, independently of both eGFR and cardiovascular risk factors, whereas eGFR provides no further information in normoalbuminuric people.
AIMS/HYPOTHESIS: Estimated glomerular filtration rate (eGFR) predicts mortality in non-diabetic populations, but its role in people with type 2 diabetes is unknown. We assessed to what extent a reduction in eGFR in people with type 2 diabetes predicts 11-year all-cause and cardiovascular mortality, independently of AER and other cardiovascular risk factors. MATERIALS AND METHODS: The study population was the population-based cohort (n = 1,538; median age 68.9 years) of the Casale Monferrato Study. GFR was estimated by the abbreviated Modification of Diet in Renal Disease Study equation. RESULTS: At baseline, the prevalence of chronic kidney disease (eGFR <60 ml min(-1) 1.73 m(-2)) was 34.3% (95% CI 33.0-36.8). There were 670 deaths in 10,708 person-years of observation. Hazard ratios of 1.23 (95% CI 1.03-1.47) for all-cause mortality and 1.18 (95% CI 0.92-1.52) for cardiovascular mortality were observed after adjusting for cardiovascular risk factors and AER. When five levels of eGFR were analysed we found that most risk was conferred by eGFR 15-29 ml min(-1) 1.73 m(-2), whereas no increased risk was evident in people with eGFR values between 30 and 59 ml min(-1) 1.73 m(-2). In an analysis stratified by AER categories, a significant increasing trend in risk with decreasing eGFR was evident only in people with macroalbuminuria. CONCLUSIONS/ INTERPRETATION: Our study suggests that in type 2 diabetes macroalbuminuria is the main predictor of mortality, independently of both eGFR and cardiovascular risk factors, whereas eGFR provides no further information in normoalbuminuric people.
Authors: Richard J MacIsaac; Sianna Panagiotopoulos; Karen J McNeil; Trudy J Smith; Con Tsalamandris; Huming Hao; P Geoffrey Matthews; Merlin C Thomas; David A Power; George Jerums Journal: Diabetes Care Date: 2006-07 Impact factor: 19.112
Authors: A P S Kong; W Y So; C C Szeto; N N Chan; A Luk; R C W Ma; R Ozaki; V W S Ng; C S Ho; C W K Lam; C C Chow; C S Cockram; J C N Chan; P C Y Tong Journal: Kidney Int Date: 2006-01 Impact factor: 10.612
Authors: H Yokoyama; S Araki; M Haneda; M Matsushima; K Kawai; K Hirao; M Oishi; K Sugimoto; H Sone; H Maegawa; A Kashiwagi Journal: Diabetologia Date: 2012-04-04 Impact factor: 10.122
Authors: V M Cambuli; M Galdiero; M Mastinu; F Pigliaru; R S Auriemma; A Ciresi; R Pivonello; M Amato; C Giordano; S Mariotti; A Colao; M G Baroni Journal: J Endocrinol Invest Date: 2011-04-28 Impact factor: 4.256
Authors: Michael Resl; Greisa Vila; Roland Kraxner; Richard Pacher; Anton Luger; Martin Hülsmann; Stephanie Neuhold; Helmut Brath; Rudolf Prager; Martin Clodi Journal: Wien Klin Wochenschr Date: 2013-09-06 Impact factor: 1.704
Authors: Ian H de Boer; Ronit Katz; Jie J Cao; Linda F Fried; Bryan Kestenbaum; Ken Mukamal; Dena E Rifkin; Mark J Sarnak; Michael G Shlipak; David S Siscovick Journal: Diabetes Care Date: 2009-07-08 Impact factor: 19.112